Bimatoprost Ophthalmic
Phase 1
Bimatoprost Ophthalmic is one of 14 therapeutic programs targeting Graves ophthalmopathy. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
13
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
13 competitors in Graves Ophthalmopathy
#DrugCompanyPhaseTrials
1Zolymbus
AbbVieApproved
Medrol
PfizerApproved
Zocor
OOrganon and Co
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Rayos
RRoxane Laboratories
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Tapazole
VViking Therapeutics, Inc.
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Bimatoprost Ophthalmic. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company
- JJohns Hopkins University